** Brokerage Citi initiates coverage on 89bio ETNB.O with "buy" rating
** Brokerage sets PT at $25, representing a near triple upside to the stock's last close
** Citi remains optimistic about co's experimental drug, pegozafermin, for patients with a type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH)
** "If 89bio can replicate its early results of pegozafermin in larger trials and show a synergistic effect when used in combination of GLP-1s, pegozafermin could become a significant player in the MASH space", says Citi
** Eight of 9 brokerages rate the stock "buy" or higher, 1 "hold"; their median PT is $29.67, according to data compiled by LSEG
** Up to last close, ETNB has fallen 35.1% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。